Shanghai Vitalgen BioPharma Co., Ltd. (hereinafter referred to as "Vitalgen") recently announced that its proprietary lipid nanoparticle (LNP) delivery technology platform has successfully entered into four technology out-licensing agreements. Partners' related R&D pipelines have subsequently received IND approvals or have advanced to the IIT (Investigator-Initiated Trial) stage.
Ø A Globally Leading Lipid Nanoparticle Delivery Technology Platform
ViLNP® is a non-viral delivery technology platform independently developed by Vitalgen. It encompasses core modules including an ionizable lipid library, multi-tissue passive targeting formulations, and active targeting delivery technologies. Currently, the key technology modules that have been successfully implemented include:
Third-Generation Ionizable Lipid Molecule L52715: Exhibits industry-leading delivery efficiency and a high metabolic profile, with only 0.03% of the parent molecule remaining in vivo after 24 hours. This supports high-dose and high-frequency repeat dosing;
Ultra-High Tolerability Liver-Tropic LNP: Demonstrates exceptional delivery efficiency with a toxic dose threshold over 10-fold higher than classical LNPs. It is suitable for applications in high-dose gene editing and protein replacement therapies;
APC-Targeted LNP (Dakini): Enables cross-organ, APC-specific mRNA delivery with "zero delivery" to hepatocytes. This technology holds promise for advancing tumor neoantigen vaccine development;
Antibody-Conjugated Targeted LNP (Ab-tLNP): Utilizes the proprietary CLAMP (Controlled Ligand Attachment on Manufacturable Particles) technology for scalable production, achieving highly specific, active cell targeting in vivo.
Ø Patent Moat and FTO Assurance
The ViLNP® platform has secured a global patent portfolio for its multiple technologies, establishing a robust intellectual property protection network that serves as a solid "patent moat" for its core technologies. Key modules have undergone Freedom-to-Operate (FTO) analyses, providing strong assurance regarding the compliance, clarity, and sustainability of the commercialization pathway.
Ø Technology Licensing Partnerships Validate Platform Value
To date, the ViLNP® platform has entered into four out-licensing agreements covering various cutting-edge fields, including universal mRNA tumor vaccines, metabolic diseases, personalized mRNA tumor vaccines, in vivo CAR-T, and in vivo gene editing. This fully demonstrates its broad application potential and appeal for collaboration:
A collaboration with Therorna supports its circular RNA therapeutic tumor vaccine project (which has received IND approval);
A license granted to an innovative biotech company for the use of L52715 in multiple pipeline programs focused on liver delivery;
An exclusive license agreement with GRIT Biotechnology for the Dakini technology (APC-targeting LNP) in the field of personalized tumor vaccines. The mRNA vaccine candidate GT601, based on this technology, is being prepared for IIT initiation.
A license agreement with GRIT Biotechnology for the Ab-tLNP technology for in vivo CAR-T applications. GT801, a next-generation in vivo CAR-T product based on this technology, is also being prepared for IIT initiation.
Furthermore, Vitalgen is advancing pre-licensing technology validation studies and research collaborations with multiple cell and gene therapy companies globally, continuously promoting the international adoption and multi-indication exploration of the ViLNP® platform.
Dr. Zhao Xiaoping, Chairman and CEO of Vitalgen, stated, "The extensive licensing and collaborations surrounding the ViLNP® platform reflect Vitalgen's strategic commitment to open innovation and mutual success. They further validate our global leadership position in the non-viral delivery field and the industry's strong recognition of Vitalgen's technological value."